Altered expression of MLL methyltransferase family genes in breast cancer

Rabello,Doralina  do Amaral; de Moura,Carolina Amaro; de Andrade,Rosangela  Vieira; Motoyama,Andrea  Barretto; Silva,Fabio  Pittella

doi:10.3892/ijo.2013.1981

Altered expression of MLL methyltransferase family genes in breast cancer

Authors:
- Doralina do Amaral Rabello
- Carolina Amaro de Moura
- Rosangela Vieira de Andrade
- Andrea Barretto Motoyama
- Fabio Pittella Silva
View Affiliations

Affiliations: Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasília, Brasília, DF 70.910-900, Brazil, Laboratory of Genomic Sciences and Molecular Biotechnology, Catholic University of Brasília, Brasília, DF 70790-160, Brazil
Published online on: June 10, 2013 https://doi.org/10.3892/ijo.2013.1981
Pages: 653-660

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The histone lysine methyltransferases contain a SET domain, which catalyzes the addition of methyl groups to specific lysine residues. The MLL family of genes encodes histone-modifying enzymes with histone 3-lysine 4 methyltransferase activity that can regulate gene transcription. The MLL family exists in multi-protein complexes and has been implicated in a variety of processes including normal development and cell growth. Although some of the MLL family members have already been described to be involved in cancer, a clear relationship of these genes with breast cancer is not determined to date. In the present study, we used quantitative PCR to investigate the expression profile of all five MLL genes [MLL (ALL-1), MLL2, MLL3, MLL4 and MLL5] in 7 breast cancer cell lines, 8 breast tumors and adjacent non-tumor tissues and in 12 normal tissues. We observed a diminished expression of all five genes in the breast cancer cell lines when compared to normal breast tissue. We found a significantly decreased expression of MLL2 in the tumor samples compared to the non-tumor controls. In tumor samples, MLL5 also showed a clear suppression tendency. Among the normal tissues analyzed, all genes showed a markedly higher expression in skeletal muscle and brain. Although further studies are required to determine the exact role of these methyltransferases in cancer development, our results indicate that the suppression of MLL genes, especially MLL2 and 5, take part in modulating breast carcinogenesis. Our assessment of the MLL family gene expression patterns in a diverse set of breast cancer cell lines and in a multitude of tissue types and breast tumors should lead to increasingly detailed information on the involvement of these genes in cancer progression.

View Figures

View References

1.	IARC: World Cancer Report. IARC; Lyon: 2008
2.	INCA: Estimativa 2012: Incidência de câncer no Brasil. INCA Rio de Janeiro; 2011, (In Portuguese).
3.	Castro N, Osório C, Torres C, et al: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 10:R872008. View Article : Google Scholar
4.	Tamimi R, Baer H, Marotti J, et al: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 10:R672008. View Article : Google Scholar : PubMed/NCBI
5.	Sjöblom T, Jones S, Wood L, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006.
6.	Deng L-W, Chiu I and Strominger J: MLL 5 protein forms intra-nuclear foci and overexpression inhibits cell cycle progression. Proc Natl Acad Sci USA. 101:757–762. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Ayton P and Cleary M: Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 20:5695–5707. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Yu B, Hess J, Horning S, Brown G and Korsmeyer S: Altered Hox expression and segmental identity in Mll-mutant mice. Nature. 378:505–508. 1995. View Article : Google Scholar : PubMed/NCBI
9.	McKinnell I, Ishibashi J, Le Grand F, et al: Pax7 activates myogenic genes by recruitment of a histone methyltransferase complex. Nat Cell Biol. 10:77–84. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Aziz A, Liu Q-C and Dilworth F: Regulating a master regulator: establishing tissue-specific gene expression in skeletal muscle. Epigenetics. 5:691–695. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Ruault M, Brun M, Ventura M, Roizès G and De Sario A: MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene. 284:73–81. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Lee J, Kim D-H, Lee S, et al: A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci USA. 106:8513–8518. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Glaser S, Schaft J, Lubitz S, et al: Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development. 133:1423–1432. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Emerling B, Bonifas J, Kratz C, et al: MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 21:4849–4854. 2002.PubMed/NCBI
15.	Sebastian S, Sreenivas P, Sambasivan R, et al: MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression and promotes myogenic differentiation. Proc Natl Acad Sci USA. 106:4719–4724. 2009. View Article : Google Scholar
16.	Madan V, Madan B, Brykczynska U, et al: Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. Blood. 113:1444–1454. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Ansari K, Kasiri S, Hussain I and Mandal S: Mixed lineage leukemia histone methylases play critical roles in estrogen-mediated regulation of HOXC13. FEBS J. 276:7400–7411. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Mo R, Rao S and Zhu Y-J: Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem. 281:15714–15720. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Ansari K, Hussain I, Kasiri S and Mandal S: HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. J Mol Endocrinol. 48:61–75. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Neve R, Chin K, Fridlyand J, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 14:518–527. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Sims R, Nishioka K and Reinberg D: Histone lysine methylation: a signature for chromatin function. Trends Genet. 19:629–639. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Miremadi A, Oestergaard M, Pharoah P and Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet. 16:R28–R49. 2007. View Article : Google Scholar
25.	Hamamoto R, Silva F, Tsuge M, et al: Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97:113–118. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Chang CJ and Hung MC: The role of EZH2 in tumour progression. Br J Cancer. 106:243–247. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Al Sarakbi W, Sasi W, Jiang W, Roberts T, Newbold R and Mokbel K: The mRNA expression of SETD2 in human breast cancer: correlation with clinicopathological parameters. BMC Cancer. 9:2902009.PubMed/NCBI
28.	Nishikawa N, Toyota M, Suzuki H, et al: Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 67:9649–9657. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Canaani E, Nakamura T, Rozovskaia T, et al: ALL-1/MLL1, a homologue of Drosophila trithorax, modifies chromatin and is directly involved in infant acute leukaemia. Br J Cancer. 90:756–760. 2004.
30.	Patani N, Jiang W, Newbold R and Mokbel K: Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res. 31:4115–4125. 2011.PubMed/NCBI
31.	Liu H, Takeda S, Kumar R, et al: Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature. 467:343–346. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Huntsman D, Chin S, Muleris M, et al: MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene. 18:7975–7984. 1999. View Article : Google Scholar : PubMed/NCBI
33.	Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 476:298–303. 2011. View Article : Google Scholar : PubMed/NCBI
34.	Pasqualucci L, Trifonov V, Fabbri G, et al: Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 43:830–837. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Dalgliesh G, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 463:360–363. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Guo C, Chang CC, Wortham M, et al: Global identification of MLL2-targeted loci reveals MLL2’s role in diverse signaling pathways. Proc Natl Acad Sci USA. 109:17603–17608. 2012.PubMed/NCBI
37.	Wang X-X, Fu L, Li X, et al: Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res. 17:429–433. 2011. View Article : Google Scholar : PubMed/NCBI
38.	Parsons D, Li M, Zhang X, et al: The genetic landscape of the childhood cancer medulloblastoma. Science. 331:435–439. 2011. View Article : Google Scholar : PubMed/NCBI
39.	Watanabe Y, Castoro R, Kim H, et al: Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One. 6:e233202011. View Article : Google Scholar : PubMed/NCBI
40.	Damm F, Oberacker T, Thol F, et al: Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol. 29:682–689. 2011. View Article : Google Scholar : PubMed/NCBI